Scleroderma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 96: | Line 96: | ||
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ||
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ||
** 2.2 '''Esophageal dysmotility''' | ** 2.2 '''Esophageal dysmotility''' | ||
**: '''Note (1):''' | **: '''Note (1):''' | ||
| Line 115: | Line 107: | ||
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ||
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ||
* 2 '''Treatment of pulmonary manifestations''' | * 2 '''Treatment of pulmonary manifestations''' | ||
| Line 141: | Line 121: | ||
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ||
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ||
** 2.2 '''Interstitial lung disease''' | ** 2.2 '''Interstitial lung disease''' | ||
**: '''Note (1):''' | **: '''Note (1):''' | ||
| Line 160: | Line 132: | ||
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | ||
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days | ||
==References== | ==References== | ||
Revision as of 23:32, 22 April 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma medical therapy On the Web |
|
American Roentgen Ray Society Images of Scleroderma medical therapy |
|
Risk calculators and risk factors for Scleroderma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Scleroderma
- 1 Treatment of skin manifestations
- 1.1 Localized Ssc - morphea
- 1.1.1 Adult
- Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
- Preferred regimen (3): drug name 500 mg q12h for 14-21 days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
- 1.1.1 Adult
- 1.2 Diffuse sclerosis of the skin
- 1.2.1 Adult
- Preferred regimen (1): methotrexate
- Alternative regimen (1): mycophenolate mofetil 500 mg PO q12h for 7-14 days, then increase to maintenance dose of 500 mg to 1500 mg PO q12h as tolerated[1]
- Alternative regimen (2): cyclophosphamide
- 1.2.1 Adult
- 1.3 Calcinosis
- 1.3.1 Adult
- Preferred regimen (1): minocycline 50-100 mg PO q12h for 6-12 weeks[2]
- Alternative regimen (1): infliximab
- Alternative regimen (2): rituximab
- 1.3.1 Adult
- 1.4 Raynaud's phenomenon
- 1.4.1 Adult
- Oral regimen
- Preferred regimen (1): Nifedipine
- Preferred regimen (2): Amlodipine
- Alternative regimen (1): Sildenafil
- Alternative regimen (2): losartan
- Topical regimen
- Alternative regimen (3): Topical nitrates
- Oral regimen
- 1.4.1 Adult
- 1.1 Localized Ssc - morphea
- 2 Treatment of gastrointestinal manifestations
- 2.1 Gastroesophageal reflux symptoms
- Note (1):
- Note (2):
- Note (3):
- 2.1.1 Adult
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
- Oral regimen
- 2.2 Esophageal dysmotility
- Note (1):
- Note (2):
- Note (3):
- 2.1 Gastroesophageal reflux symptoms
- 2 Treatment of pulmonary manifestations
- 2.1 Pulmonary arterial hypertension
- Note (1):
- Note (2):
- Note (3):
- 2.1.1 Adult
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
- Oral regimen
- 2.2 Interstitial lung disease
- Note (1):
- Note (2):
- Note (3):
- 2.1 Pulmonary arterial hypertension
References
- ↑ Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler J, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP (July 2017). "Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)". Ann. Rheum. Dis. 76 (7): 1207–1218. doi:10.1136/annrheumdis-2016-210503. PMC 5530354. PMID 28188239. Vancouver style error: initials (help)
- ↑ Robertson LP, Marshall RW, Hickling P (March 2003). "Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline". Ann. Rheum. Dis. 62 (3): 267–9. PMC 1754479. PMID 12594118.